Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Risankizumab for Plaque Psoriasis
Recruiting2 awardsPhase 3
Bellaire, Texas
This trial will evaluate whether switching from secukinumab or ixekizumab to risankizumab may help adult participants with moderate to severe plaque psoriasis who have not had an optimal response to their current treatment. The study will last for up to 64 weeks, with participants receiving risankizumab injections every 12 weeks. Physical exams and questionnaires will be collected at 8 weeks, with a final follow-up phone call at 60 weeks.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.